Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.1%

1 terminated/withdrawn out of 48 trials

Success Rate

97.1%

+10.6% vs industry average

Late-Stage Pipeline

21%

10 trials in Phase 3/4

Results Transparency

3%

1 of 33 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
24(53.3%)
Phase 2
9(20.0%)
Phase 3
6(13.3%)
Phase 4
4(8.9%)
N/A
2(4.4%)
45Total
Phase 1(24)
Phase 2(9)
Phase 3(6)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials
NCT07471867Phase 4Recruiting

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Role: collaborator

NCT07115706Not Yet Recruiting

JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

Role: lead

NCT06952855Completed

Observationa Study is a Prospective and Multi-institutional Observational Study.

Role: lead

NCT06431399Phase 1Recruiting

To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004

Role: lead

NCT06171880Phase 1Completed

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901

Role: lead

NCT06169059Phase 1Completed

To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

Role: lead

NCT06165965Phase 1Completed

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

Role: lead

NCT06144788Phase 2Unknown

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Role: lead

NCT05820048Phase 4Unknown

The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)

Role: collaborator

NCT04861233Unknown

A Study of Lubiprostone to Treat Constipation

Role: lead

NCT04335604Phase 1Completed

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Role: collaborator

NCT05296044Phase 3Unknown

To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Role: lead

NCT05101135Phase 3Unknown

To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Role: lead

NCT04917315Phase 3Completed

To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

Role: lead

NCT05172622Phase 1Unknown

Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects

Role: lead

NCT04914221Phase 1Completed

The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Role: lead

NCT01341730Phase 4Terminated

The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)

Role: collaborator

NCT03062397Phase 2Unknown

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Role: lead

NCT02972268Phase 3Completed

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

Role: lead

NCT03707899Phase 1Completed

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

Role: lead